Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma

Clin Biochem. 2011 Jun;44(8-9):590-5. doi: 10.1016/j.clinbiochem.2011.01.010. Epub 2011 Feb 12.

Abstract

Background: Multiple myeloma (MM) was the first hematological malignancy in which a prognostic relevance of bone marrow (BM) angiogenesis was reported. Microenvironment formed by reactive oxygen species, growth factors and chemokines initiates the process of BM angiogenesis. Among the angiopoietins, angiopoietin-1 is involved in vessel stability, whereas angiopoietin-2 is involved in vessel sprouting.

Design and methods: Circulatory levels of angiopoietin-1, angiopoietin-2 and VEGF in 62 MM patients and 50 healthy controls were determined using ELISA.

Results: Significant increase in VEGF and angiopoietin-2 level was observed in patients which correlated positively with the severity of the disease, whereas no alteration was observed in angiopoietin-1 levels.

Conclusion: Significant elevation in angiopoietin-2 and VEGF levels and their correlation with severity of the disease indicate their utility as potential tumor markers along with β(2)- microglobulin and might also suggest new therapeutic target for anticancer treatment.

MeSH terms

  • Adult
  • Aged
  • Angiopoietin-1 / blood
  • Angiopoietin-2 / blood*
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / blood*
  • Multiple Myeloma / diagnosis*
  • Vascular Endothelial Growth Factors / blood

Substances

  • Angiopoietin-1
  • Angiopoietin-2
  • Vascular Endothelial Growth Factors